Abbott Laboratories (NYSE: ABT) is 26.05% higher on its value in year-to-date trading and has touched a low of $61.61 and a high of $115.14 in the current 52-week trading range. The ABT stock was last observed hovering at around $108.44 in the last trading session, with the day’s gains setting it 1.05% off its average median price target of $122.00 for the next 12 months. It is also 15.78% off the consensus price target high of $130.00 offered by 21 analysts, but current levels are 1.36% higher than the price target low of $111.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Currently trading at $109.49, the stock is 1.69% and 0.65% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.88 million and changing 0.97% at the moment leaves the stock 10.78% off its SMA200. ABT registered 25.92% gain for a year compared to 6-month gain of 18.71%. The firm has a 50-day simple moving average (SMA 50) of $108.41 and a 200-day simple moving average (SMA200) of $103.98.
The stock witnessed a 0.92% loss in the last 1 month and extending the period to 3 months gives it a 0.78%, and is 1.90% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 1.35% over the week and 1.60% over the month.
Abbott Laboratories (ABT) has around 107000 employees, a market worth around $192.19B and $32.22B in sales. Current P/E ratio is 58.24 and Fwd P/E is 24.86. Profit margin for the company is 10.50%. Distance from 52-week low is 77.71% and -4.91% from its 52-week high. The company has generated returns on investments over the last 12 months (8.20%).
Abbott Laboratories (ABT) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Abbott Laboratories (ABT) is a “Overweight”. 21 analysts offering their recommendations for the stock have an average rating of 1.90, where 3 rate it as a Hold and 2 think it is a “Overweight”. 14 of the analysts rate the stock as a “Buy”. 1 analysts have rated the stock as a Sell or Underperform.
Abbott Laboratories is expected to release its quarterly report on 04/21/2021 and quarterly earnings per share for the current quarter are estimated at $1.35 with sales reaching $9.95B over the same period.The EPS is expected to grow by 45.20% this year, but quarterly earnings will post 6.20% year-over-year. Quarterly sales are estimated to grow 19.70% in year-over-year returns.
Abbott Laboratories (ABT) Top Institutional Holders
2,863 institutions hold shares in Abbott Laboratories (ABT), with 12.28M shares held by insiders accounting for 0.69% while institutional investors hold 76.11% of the company’s shares. The shares outstanding are 1.77B, and float is at 1.76B with Short Float at 0.50%. Institutions hold 75.58% of the Float.
The top institutional shareholder in the company is Vanguard Group, Inc. (The) with over 148.16 million shares valued at $16.12 billion. The investor’s holdings represent 8.36% of the ABT Shares outstanding. As of Sep 29, 2020, the second largest holder is Blackrock Inc. with 135.02 million shares valued at $14.69 billion to account for 7.62% of the shares outstanding. The other top investors are Capital Research Global Investors which holds 87.41 million shares representing 4.93% and valued at over $9.51 billion, while State Street Corporation holds 4.16% of the shares totaling 73.67 million with a market value of $8.02 billion.
Abbott Laboratories (ABT) Insider Activity
The most recent transaction is an insider sale by NOVAKOVIC PHEBE N, the company’s Director. SEC filings show that NOVAKOVIC PHEBE N sold 4,790 shares of the company’s common stock on Dec 04 at a price of $107.28 per share for a total of $0.51 million. Following the sale, the insider now owns 41004.0 shares.
Abbott Laboratories disclosed in a document filed with the SEC on Oct 26 that Funck Robert E (Executive Vice President & CFO) sold a total of 83,333 shares of the company’s common stock. The trade occurred on Oct 26 and was made at $108.83 per share for $9.07 million. Following the transaction, the insider now directly holds 0.18 million shares of the ABT stock.
Still, SEC filings show that on Sep 30, Wainer Andrea F (Executive Vice President) disposed off 30,000 shares at an average price of $107.01 for $3.21 million. The insider now directly holds 44,080 shares of Abbott Laboratories (ABT).
Abbott Laboratories (ABT): Who are the competitors?
The company’s main competitors (and peers) include Thermo Fisher Scientific Inc. (TMO) that is trading 42.72% up over the past 12 months. Johnson & Johnson (JNJ) is 7.82% up on the 1-year trading charts. Short interest in the company’s stock has fallen -33.45% from the last report on Nov 12, 2020 to stand at a total of 11.85 million short shares sold with a short interest ratio of 1.83.